Evidence Base for Vena Cava Filter Use 'Thin'
Maynard says he believes the variability is driven, if not by the dramatic increase in reimbursement to hospitals, "around local culture and a few influential physicians or thought leaders pushing the agenda."
"There's certainly a driver fiscally. And that's for the people who sell these devices, pushing them, because people are being unduly influenced by the promotion of them, thinking that they're protecting patients."
In an accompanying Viewpoint in the same JAMA issue, Vinay Prasad, MD, Jason Rho, MD, and Adam Cifu, MD, of the National Cancer Institute called for the U.S. Food and Drug Administration to step in.
They pointed out the need for studies to prove these filters benefit patients, "given the known harms and lack if efficacy data" for them.
"Unfortunately, there is little incentive for manufacturers of filters to embark on trials that can only eliminate their products market share," so the FDA should "require current filter manufacturers to perform efficacy studies of their devices as a condition for remaining on the market, or a large federally funded study to determine if this expensive device leads to greater benefit than harm."
Cheryl Clark is senior quality editor and California correspondent for HealthLeaders Media. She is a member of the Association of Health Care Journalists.
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability
- Doctors Feel Pressure to Accept Risk-based Reimbursement
- Surgical Checklists Unused in 10% of Hospitals, CMS Data Shows
- Centralizing the Revenue Cycle Protects the Bottom Line
- A Fresh Look at End-of-Life Care
- 3 in 4 Patients Want E-mail Consultations
- Heart Attack Patient Costs Skyrocket Beyond 30 Days
- CA Fines 8 Hospitals for Medical Errors
- ACGME Chief Sees 'Huge' Risk of Error in Proposed Assistant Physician Licensure
- 3 Insider Tips on Cutting Costs without Strangling Growth